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1. Introduction  
It is well known and has been shown that patients who have chronic renal failure tend to 
develop and die of cardiac causes. These patients are known to develop a cardiomyopathy 
that is characterized by left ventricular hypertrophy and significant diastolic dysfunction. 
It has also been shown that the chronic renal failure condition is characterized by 
significant sodium pump inhibition due to increases in the circulating levels of 
cardiotonic steroids (CTS) such as marinobufagenin (MBG). In this review we will try to 
elucidate the mechanisms involved in the pathogenesis of uremic cardiomyopathy and 
the role of CTS in the pathogenesis as well as the possible areas of therapeutic 
interventions. 
2. Renal failure and cardiotonic steroids 
The current treatment of patients with end stage renal failure is complicated by the tremendous 
cardiovascular mortality associated with it. Such patients tend to develop a cardiomyopathy 
characterized by marked diastolic dysfunction and left ventricular hypertrophy (LVH). These 
patients also have substantial increases in the circulating levels of CTS (Mohmand, Malhotra et 
al. 2005). Perhaps of greater importance, it has more recently been shown that patients with 
more modest degrees of chronic renal insufficiency have markedly worse outcomes in high 
cardiovascular risk settings as well as a substantial worsening of cardiovascular risk (Alsheikh-
Ali, Trikalinos et al. 2011; Kreuz, Horlbeck et al. 2011) 
It was proposed nearly 4 decades ago that there is accumulation of CTS in chronic renal 
failure that causes the inhibition of the Na/K ATPase. The patients with chronic renal 
failure developed some antibodies to digoxin and had false positive digoxin levels even 
though these patients had not been treated with digitalis (Graves 1986; Graves and Williams 
1987).  More recently using more definitive analytical techniques several of these CTS have 
been characterized. These include ouabain (Hamlyn, Blaustein et al. 1991) which is a 
cardenolide and marinobufagenin (MBG) and telocinobufagin (TBG) (Bagrov and Fedorova 
1998; Komiyama, Dong et al. 2005) which are bufadienolides. These CTS have been 
considered only as drugs until recently as studies now indicate that these compounds are 
secreted in the body and regulated by multiple physiological stimuli such as ACTH and 
angiotensin II (Fedorova, Agalakova et al. 2005; Bagrov, Shapiro et al. 2009). They have also 
been found to play an important role in renal salt handling as well as the regulation of 
cardiac contractility and vascular tone (Hamlyn, Blaustein et al. 1991; Fedorova, Doris et al. 
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1998). Recently, many other functions of these endogenous ligands of the Na/K-ATPase 
have been proposed. 
The mechanism of elevation of these CTS possibly includes a combination of decreased 
elimination and increased production, but one would anticipate an elevation as it was 
initially thought that the these hormones functioned as natriuretic hormones since the Na/K 
ATPase comprises a major sodium transporting mechanism in the kidney (de Wardener, 
Clarkson et al. 1971).  Increases in sodium levels would be caused by decreased renal 
elimination due to loss of renal function. It has also been thought that the increases in the 
CTS effect vasoconstriction by inhibition of Na/K ATPase causing coupled activation of the 
Na/Ca exchanger in the vascular smooth muscles (Jaitovich and Bertorello 2010). Bricker 
and colleagues postulated that in order to maintain sodium homeostasis in renal failure, 
increases in circulating CTS were necessary, but the effects of CTS on other tissues other 
than the kidneys explained many of the clinical features seen in renal failure. This was 
termed as the trade off hypothesis for the pathogenesis of the ‘uremic syndrome’ (Bricker 
and Fine 1978) and is illustrated in figure 1.  Now it is well known that the reduced pump 
activity has been seen in red cells, white blood cells, transporting epithelia, muscle cells, 
adipocytes and the cardiomyocytes (Stokes, Willcocks et al. 1986; Okamoto 1988; Takahashi, 
Nishimura et al. 1989; Mimura, Makino et al. 1992; Periyasamy, Chen et al. 2001). 
 
 
Fig. 1. Illustration of the role of cardiotonic steroids (CTS) in “trade off.” With decreased 
filtering function, CTS concentrations increase to maintain sodium homeostasis, but these 
elevated hormone levels have adverse effects on different tissues. 
Ouabain the prototypical CTS described in 1991 by Hamlyn and colleagues (Hamlyn, 
Blaustein et al. 1991) was initially thought to function as the natriuretic peptide responsible 
for the effects seen. However it is well known now that ouabain has high affinity to the 
alpha 2 and 3 isoforms of Na/K ATPase where as rat tubular cells mainly express the alpha 
1 isoform which is relatively insensitive to ouabain (Sweadner 1989). However in humans 
the sensitivity of the different isoforms to ouabain seems to be not that significant (Croyle, 
Woo et al. 1997; Lingrel 2010). It is now known that ouabain probably has a more neuro-
hormonal function and has been isolated from the hypothalamus and the hippocampus 
(Kawamura, Guo et al. 1999; Fedorova, Zhuravin et al. 2007). A new body of evidence is 
emerging that brain ouabain may play important role in pathogenesis of salt sensitive 
hypertension (Fedorova, Zhuravin et al. 2007).  
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More recently other CTS have been described such as MBG and TBG, which has a structure 
very similar to that of MBG (Bagrov, Roukoyatkina et al. 1993; Komiyama, Dong et al. 2005). 
They were seen to be elevated significantly in plasma of ESRD patients. The bufadienolides 
were first described from the skin of amphibians such as the marine toad (Bufo marinus) 
(Bagrov, Shapiro et al. 2009) and MBG emerged as the most important contender since it has 
the affinity towards the alpha 1 isoform which is the isoform present almost exclusively in 
the mammalian tubules. MBG at low doses also causes vasoconstriction in isolated human 
blood vessels (Bagrov, Roukoyatkina et al. 1995). Bagrov and colleagues have demonstrated 
that the levels of MBG are elevated in response to both salt loading and in the presence of 
experimental renal failure (Fedorova, Agalakova et al. 2005). They have also demonstrated 
the role of ouabain as a neuro-hormone by intra-hippocampal administration of ouabain 
and demonstrating an increase in the plasma and urine concentration of MBG as well as 
increased natriuresis from this (Fedorova, Agalakova et al. 2005). Also it has been shown 
that the synthesis of these CTS occurs in the mammalian adrenal cells; however the specific 
metabolic steps in this biosynthesis are still unknown (Dmitrieva, Bagrov et al. 2000). 
3. Signaling though the sodium pump 
Signaling though the sodium pump has been studied extensively in the recent years and our 
knowledge about the process has considerably increased. It is well known that there is more 
than just the ‘classical enzymatic inhibition’ causing increases in cytosolic sodium (Jaitovich 
and Bertorello 2010). One concern is that the circulating levels of CTS seen in pathological 
conditions do not appear to cause extensive inhibition of the pump in vitro and in vivo 
(Bagrov, Shapiro et al. 2009). In fact, the growth regulatory effects of CTS are seen even at 
nano and sub-nano molar concentrations, which do not cause any demonstrable inhibition 
of the pump activity (Aydemir-Koksoy, Abramowitz et al. 2001; Aydemir-Koksoy and Allen 
2001; Saunders and Scheiner-Bobis 2004; Khundmiri, Metzler et al. 2006; Qiu, Gao et al. 
2007). Another concern is that it has been difficult if not impossible to demonstrate changes 
in cytosolic sodium caused by physiological and even pharmacological concentrations of 
CTS. Perhaps more troubling, small increases in the cytosolic sodium levels caused by pump 
inhibition would be expected to minimize effects on net Na/K-ATPase activity by mass 
action as cytosolic Na is generally maintained at concentrations where it can actually 
regulate pump activity. Last but most significantly, sodium ionophores do not cause the 
biological effects of CTS (Liu, Tian et al. 2000; Oweis, Wu et al. 2006).  
While the classical pathway of pump inhibition may still explain some of the effects of CTS, 
a novel signal cascade involving the Na/K-ATPase residing in specific membrane 
environments has been proposed and documented by Xie and others (Li and Xie 2009). This 
research performed on neonatal rat cardiac myocytes showed that ouabain caused the Na/K 
ATPase to interact with neighboring membrane proteins and caused cytosolic cascades of 
signaling. The administration of ouabain to the cardiomyocytes caused an increase in 
reactive oxygen species (ROS) (Liu, Tian et al. 2000). It was seen from the experiments that 
first there was phosphorylation of Src and leading to the activation of Ras. This trans-
activated the EGFR and triggered a signaling cascade that led to the production of ROS 
(Haas, Askari et al. 2000; Liu, Tian et al. 2000; Kometiani, Askari et al. 2001; Haas, Wang et 
al. 2002; Wang, Haas et al. 2004; Tian, Cai et al. 2006). Also it has been shown that these ROS 
were key in the signaling function of Na/K ATPase. The administration of N Acetyl 
Cysteine (NAC) or green tea extract which act as ROS quenchers blocked the gene 
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transcription effects of CTS (Xie, Kometiani et al. 1999; Liu, Tian et al. 2000; Priyadarshi, 
Valentine et al. 2003; Elkareh, Kennedy et al. 2007).  At present it is unclear as to how ROS 
effect downstream signaling. One possibility albeit unproven is that the Na/K ATPase itself 
may serve as a receptor for the ROS enhancing its sensitivity by conformational change. 
Further work in this exciting area is currently underway. Development of ROS in response 
to sodium pump signaling is shown in figure 2. 
 
 
Fig. 2. Schematic showing how cardiotonic steroids (CTS) change the conformation of the 
Na/K-ATPase residing in caveolae or lipid rafts, allowing Src to transactivate the EGFR and 
cause signal transduction through RAS resulting in the generation of reactive oxygen 
species (ROS). 
Several studies have shown that low concentrations of ouabain have stimulated tyrosine 
phosphorylation of several proteins in a variety of cells including cardiac myocytes, HeLa 
and LLC-PK1 cells (Kometiani, Li et al. 1998; Contreras, Shoshani et al. 1999; Haas, Askari et 
al. 2000; Aydemir-Koksoy, Abramowitz et al. 2001; Kometiani, Liu et al. 2005; Kotova, Al-
Khalili et al. 2006; Kotova, Galuska et al. 2006). Importantly the addition of tyrosine kinase 
inhibitors like herbimycin A and genistein, blocked ouabain induced tyrosine 
phosphorylation and subsequently the downstream effects in these cultured cells (Haas, 
Askari et al. 2000; Aydemir-Koksoy, Abramowitz et al. 2001). Tyrosine phosphorylation can 
occur in one of two ways, either by activation of tyrosine kinases or by inhibition of tyrosine 
phosphatases or a combination of both. The Na/K ATPase does not have intrinsic tyrosine 
kinase activity. It is interesting that even though the alpha subunit has a phosphatase 
activity, preliminary studies suggest that it does not have significant tyrosine phosphatase 
activity (Li and Xie 2009). However, it has clearly been shown that ligands extrinsic to the 
Na/K-ATPase signal cascade can stimulate tyrosine kinase activity by employing receptors 
without any intrinsic tyrosine kinase activity (Ihle and Kerr 1995; McGarrigle and Huang 
2007). One such demonstrated pathway is the G protein coupled receptors (GPCRs) that 
employ the Src family of kinases (McGarrigle and Huang 2007). It was hence postulated that 
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the Src family of kinases could play a role in the ouabain induced tyrosine phosphorylation 
(McGarrigle and Huang 2007). 
Studies done by Haas et al. have indeed shown that Src is involved in the phosphorylation 
of proteins in CTS signaling. These studies showed that ouabain caused stimulation of Src in 
cardiac myocytes as well as LLC-PK1 cells. Inhibition of Src blocked the ouabain-induced 
phosphorylation and abolished the downstream signaling including the activation of ERK 
(Haas, Askari et al. 2000; Haas, Wang et al. 2002). Furthermore there is sufficient evidence 
for the fact the Na/K ATPase interacts with Src and forms a functional receptor complex. 
These workers observed that the pump and Src could be co-localized in the caveolar 
fractions in several different types of cells. Also immunofluorescence showed the co-
localization of these two in the plasma membrane. Both the proteins could also be co-
immunoprecipitated by using antibodies to either alpha 1 and to Src. Fluorescence 
resonance energy transfer (FRET) has also shown these two proteins to be in close proximity 
(Liu, Mohammadi et al. 2003; Wang, Haas et al. 2004; Liang, Cai et al. 2006; Tian, Cai et al. 
2006). They have also showed that the interaction between the Na/K ATPase and Src keeps 
Src in an inactive state. It was seen that when ouabain binds to the sodium pump it reduced 
the binding of the Src Kinase domain. This freeing of the Src kinase domain possibly results 
in the activation of the Na/K ATPase associated Src kinase (Tian, Cai et al. 2006). 
Additionally experiments were done to see if the loss or knockdown of Na/K ATPase 
would release the interacting Src and increase in tyrosine kinase activity. Graded 
knockdown of LLC-PK1 cells with alpha 1 specific siRNA was achieved and Src activity was 
studied. It was seen that the knockdown of the pump resulted in an increase in basal Src 
activity in an alpha 1 amount dependent manner. Tyrosine phosphorylation of several 
protein molecules was also increased secondary to this. Moreover stimulation of these cells 
with ouabain failed to stimulate Src and ERK 1 and 2 any further. When these knockdown 
cells were rescued with rat alpha 1, it restored Src to its basal levels and allowed for 
stimulation of the complex at higher levels of Ouabain as would be expected with the 
differences in sensitivity of rat versus pig alpha 1 (Liang, Cai et al. 2006).  
It is also known that the binding of ouabain to the receptor complex leads to the recruitment 
and transactivation of the EGFR. This was due to the Src dependent phosphorylation of the 
EGFR at sites other than the major auto-phosphorylation site Y1173. The transactivated 
EGFR in turn recruited Shc to the complex and resulted in the activation of the 
Ras/Raf/MEK/ERK cascade (Haas, Askari et al. 2000; Aydemir-Koksoy, Abramowitz et al. 
2001; Haas, Wang et al. 2002; Kotova, Al-Khalili et al. 2006). Further studies have shown that 
once the Src Na/K ATPase complex has been activated it leads to the synthesis of ROS, 
which has been thought of as a second messenger.  It has been demonstrated by Xie and 
coworkers that exposure of myocytes to ouabain causes a rapid increase in the generation of 
ROS. These ROS were demonstrated with the help of a fluorescence dye CMDCF. The 
generation of the ROS was prevented by pre-treatment of the cells to anti-oxidants such as N 
Acetyl Cysteine (NAC) and Vitamin E. By studying the blockade of the downstream 
signaling it was seen that ROS is involved with the signaling causing stimulation of Ras, 
activation of p42/44 mitogen-activated protein kinases, induction of genes for skeletal 
muscle actin and atrial natriuretic peptide and the activation and translocation of the 
transcription factor NF-κB among several other effects (Xie, Kometiani et al. 1999). Since a 
lot of these are calcium dependent steps further experiments were done to see if the ROS 
production was calcium dependent as well. Ouabain caused the production of ROS in 
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myocytes that were stimulated in culture media that were calcium deficient. This indicated 
that the production of ROs was calcium independent and possibly the increases in calcium 
was due to a parallel mechanism from the inhibition of the sodium pump activity (Liu, Tian 
et al. 2000) 
Sites of generation and targets of ROS are currently being worked out, with clues in 
favor of Ras activation induced mitochondrial production (Liu, Tian et al. 2000)however 
other components of the downstream signaling including the involvement of PLC, PI3K 
and PKC have been established.  Src activation led to the stimulation of PLC gamma and 
subsequently the activation of PKC and PI3 mediated calcium signaling. Moreover it was 
seen that ouabain also stimulates PI3K which works with PKC to cause endocytosis of 
this sodium pump complex. This probably is the explanation for how the signal 
transduction is eventually terminated. (Tian, Liu et al. 2003; Liu, Liang et al. 2005; Yuan, 
Cai et al. 2005; Pierre, Yang et al. 2007; Chen, Cai et al. 2008; Elkareh, Periyasamy et al. 
2009). 
This signaling pathway may link to Bricker’s concept of CTS as a natriuretic hormone. 
Specifically, our group has noted that CTS induce endocytosis of the Na/K-ATPase in 
kidney tissues. In chronically salt loaded Sprague-Dawley rats, renal MBG excretion was 
significantly elevated and anti-MBG antibody reduced natriuresis and restored sodium 
pump activity in the renal cortex (Periyasamy, Liu et al. 2005). The same study 
demonstrated that in addition to the direct inhibition of the Na/K-ATPase, MBG is capable 
to exhibit its natriuretic via internalization of the sodium pump in the proximal tubule 
(Periyasamy, Liu et al. 2005). The endocytosis of the proximal tubular Na/K-ATPase 
induced by CTS has been shown to proceed through clathrin coated pits and require PI3K 
activation as well as the plasmalemmal pump being in the context of caveolae as well as 
signaling through the Src–EGFR pathway (Liu, Kesiry et al. 2004; Liu, Liang et al. 2005). 
Further work demonstrated that CTS could induce decreases in the apical expression of one 
of the plasma membrane Na+/H+ exchanger, NHE3 (Oweis, Wu et al. 2006; Liu and Shapiro 
2007). Taken together, these data suggest that increases in the circulating levels of MBG 
accompany salt loading, which, in turn, may induce decreases in both basolateral and apical 
sodium transport in the proximal tubule. 
4. Uremic cardiomyopathy 
It is a well-known fact that cardiovascular mortality accounts for more that 50% of all deaths 
in patients with renal failure. It is seen that this mortality is more attributed to cardiac 
failure and sudden cardiac death than coronary events (Sarnak, Levey et al. 2003; Weiner, 
Tighiouart et al. 2004). Available data also suggests that pre end stage renal disease (ESRD) 
patients have cardiac mortality rates very similar to that of ESRD patients (Stack and 
Bloembergen 2001; Paparello, Kshirsagar et al. 2002; Sarnak 2003; Sarnak, Levey et al. 2003). 
Echocardiography has shown that diastolic dysfunction and LVH are both very common in 
ESRD patients on dialysis and other patients with chronic kidney disease (Harnett, Parfrey 
et al. 1988; Mitsnefes, Daniels et al. 2001; Stack and Saran 2002). Systolic dysfunction in these 
patients is less uniformly demonstrable (Raj, D'Mello et al. 1997) and it has been shown that 
development of LVH may be a predictor of higher mortality in dialysis patients (Nakazato, 
Kawada et al. 2002; Tyralla and Amann 2003) as this correlates with the  development of 
cardiac arrhythmias. 
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Of late myocardial fibrosis that was described in uremia as early as 1943 by Rossle and then 
described again by Ritz et al. seems to play a very important role in the pathogenesis (Mall, 
Huther et al. 1990). It has been shown by the same group that the fibrosis occurred early 
after subtotal nephrectomy without myocardial necrosis suggesting a reactive fibrosis rather 
than a reparative fibrosis. It was seen that the interstitial volume density increased at the 
expense of capillary volume and this caused the swelling of the cytoplasm and nuclei of the 
interstitial cells where as the endothelial cells remained unchanged (Mall, Rambausek et al. 
1988). The cardiac fibrosis can explain the abnormalities in the left ventricular compliance 
causing diastolic dysfunction as well as inhomogeneity in the electrical conduction causing 
arrhythmias. The factors thought to be involved in the genesis of myocardial fibrosis and 
LVH include anemia, hypertension, hyperparathyroidism, cardiotonic steroids, oxidative 
stress and the activation of the RAS aldosterone system. 
Of the above-mentioned factors anemia seems to be the weakest to be implicated in uremic 
cardiomyopathy. Only a very modest improvement in LVH to the tune of 10-20% has been 
seen with sustained increases in hematocrit (Foley, Parfrey et al. 2000). Also the LVH seen is 
concentric in nature which is not what would be expected with anemia (Harnett, Parfrey et 
al. 1988). Interestingly erythropoietin therapy worsened LVH possibly because of worsening 
BP control (Minagawa, Hirano et al. 1994). 
Among the several implicated factors hypertension seems to be the factor in chronic renal 
failure that is best linked to LVH (Huting and Alpert 1992; Morduchowicz, Zabludowski et 
al. 1993; Harnett and Parfrey 1994). Although there is sufficient evidence to prove that 
hypertension causes LVH, it does not account for the frequency and severity of LVH seen in 
ESRD patients (Huting and Alpert 1992; Foley and Parfrey 1998; Nishikimi, Minami et al. 
2001). Hence this points to the presence of other factors in the pathogenesis. However 
hypertension must be aggressively pursued in patients with renal failure as treatment has 
resulted in a modest amelioration of LVH (Dyadyk, Bagriy et al. 1997). 
It also seems that the activation of the renin angiotensin aldosterone axis seems to be a factor 
independent of hypertension. Experimental studies by Diez et al. and Ritz et al. have shown 
that the activation of this system in involved in the genesis of cardiac fibrosis (Amann, 
Simonaviciene et al. 2001; Diez, Lopez et al. 2001; Diez 2004; Gonzalez, Lopez et al. 2004). In 
conjunction with this Pirola et al. have also shown that angiotensin II also stimulated the 
release of PTH (Pirola, Wang et al. 1993; Okano, Wu et al. 1994) and in the next section we 
will discuss how PTH seems to be an important factor in causing fibrosis and LVH. It has 
been shown that treatment with ACE inhibitors causes regression of LVH independent of 
hypotensive effects (Cannella, Paoletti et al. 1997; Dyadyk, Bagriy et al. 1997; Vlahakos, 
Hahalis et al. 1997). This lends more credibility to the idea that cardiac fibrosis may be an 
important factor in the pathogenesis of uremic cardiomyopathy. 
Hyperparathyroidism has been proposed to be a factor as it causes abnormalities in cardiac 
energy metabolism and growth. Calcium ions are very important for the myocardial 
excitation contraction coupling and the cardiac contraction and relaxation. The release of 
calcium from the sarcoplasmic reticulum is the key step in the initiation of the coupling. 
Dissociation and sequestration of the calcium by an energy dependent pump like SERCA 
produces relaxation. The intracellular calcium homeostasis seems to be maintained by the 
membrane bound Na/Ca exchanger and SERCA which in turn is dependent on Na/K 
ATPase and Na/H exchanger (Morgan 1991). Both parathyroid hormone (PTH) and 
Parathyroid hormone related peptide (PTHrP) have been shown to acutely increase the force 
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of contraction in isolated beating rat cardiac myocytes (Wang, Wu et al. 1993; Smogorzewski 
1995). PTH excess in uremic patients has also been shown to increase cytosolic calcium 
levels that were correlated with the plasma PTH concentrations. These were also shown to 
be corrected with parathyroidectomy (PTX) (Raine, Bedford et al. 1993). Even though 
increased calcium entry has been thought to be the most important step in sustaining high 
intra myocyte calcium concentrations reductions in the NA/K ATPase and Na/H exchange 
rates suggesting impaired calcium extrusion may contribute to altered cellular calcium 
homeostasis (Smogorzewski 1995). Parathyroid hormone (PTH) now is known to cause 
increased endocytosis of Na/K ATPase and this may amplify CTS mediated signaling 
through the sodium pump (Khundmiri, Bertorello et al. 2004). Baczynski el al. have also 
reported that there is uncoupling of the oxidative phosphorylation and inhibited myocardial 
energy production in isolated myocardial mitochondria which may further this problem 
(Baczynski, Massry et al. 1985). 
In humans with ESRD the presence of secondary hyperparathyroidism has been shown to be 
associated with increased myocardial calcium content and impaired systolic and diastolic 
functions. However these changes have not consistently been seen to improve with PTX 
suggesting that in the long term these changes induced by PTH become irreversible or there 
are other factors contributing to the myocardial dysfunction that are more important than just 
PTH excess (Drueke, Fauchet et al. 1980; Rostand, Sanders et al. 1988; Coratelli, Buongiorno et 
al. 1989; Ohara, Hiramatsu et al. 1995; Rostand and Drueke 1999). In reference to this the 
presence of 1,25 (OH)2 D3 receptors have been confirmed on the myocardial cells and the 
administration of Vitamin D in ESRD patients seems to correct the cardiac dysfunction either 
by correcting the excessive secretion of PTH or by a Vitamin D dependent process in the 
cardiac cells (Coratelli, Petrarulo et al. 1984; Shane, Mancini et al. 1997).  
Our group has focused attention on CTS in the pathogenesis of uremic cardiomyopathy.  
Along with acute impairment of relaxation in normal adult rat cardiomyocytes when 
exposed to MBG (Periyasamy, Chen et al. 2001) experimental chronic renal failure induced 
in rats by 5/6th nephrectomy (Kennedy, Elkareh et al. 2008) causes a cardiomyopathy that is 
very similar to clinical chronic renal failure. It has been observed that LVH develops quite 
early and this is accompanied by impaired myocyte relaxation causing diastolic dysfunction. 
It seems that this impaired relaxation is associated with a significant down regulation of 
SERCA2a mRNA (Kennedy, Omran et al. 2003; Kennedy, Vetteth et al. 2006), which is 
known to be responsible for the rapid reduction of cytosolic calcium after systole (Bassani, 
Bassani et al. 1995; Bers, Bassani et al. 1996; Kennedy, Vetteth et al. 2006). Left ventricular 
catheterization in 5/6th nephrectomized rats at 4 weeks and calculation of dP/dT for 
relaxation indicated the presence of significant diastolic dysfunction (Kennedy, Vetteth et al. 
2006). LVH was also demonstrated in these hearts by echocardiography as well as increases 
in heart weights and left ventricular end systolic volumes. There were also increases in the 
posterior wall thickness. Interestingly the LVH and diastolic dysfunction were also present 
in rats that were just infused MBG using an intra-peritoneal pump, and tended to resolve in 
animals immunized with an MBG-BSA conjugate that resulted in high titer specific response 
to MBG (Kennedy, Vetteth et al. 2006). 
The animal studies done to reproduce the phenotype of cardiomyopathy by infusing with 
MBG so as to achieve plasma levels of MBG consistent with renal failure as well as induction 
of experimental renal failure by 5/6th nephrectomy, both interestingly revealed a significant 
amount of cardiac fibrosis in both the rat and the mouse. Also active immunization against the 
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MBG as discussed above as well as reduction of MBG levels by adrenalectomy prevented the 
onset of cardiac fibrosis seen in these animals. The heart tissue from these animals also showed 
evidence of activation of Na/K ATPase signaling as seen by increases in Src and MAPK 
phosphorylation. It was also demonstrated that there was significant increases in oxidant 
stress in the heart and other tissues (Kennedy, Vetteth et al. 2006). This noted fibrosis seems to 
play a significant role in the pathogenesis of uremic cardiomyopathy. 
The above studies prompted in-vitro studies on fibroblast in order to see the effects of MBG 
and other CTS such as ouabain. It was seen that in fibroblast cultures grown to confluence 
there was increased proline incorporation as well as increased collagen production. There 
was also evidence of activation of Na/K ATPase signaling as there was increased Src and 
MAPK activation. Interestingly there was evidence of increases in oxidant stress and the 
scavenging of these ROS resulted in the inhibition of the Src pathway as well as prevented 
the increases in proline incorporation and collagen synthesis (Elkareh, Kennedy et al. 2007).  
It has been further established that this fibrosis is dependent on the down regulation of Fli-1, 
which is a negative regulator of collagen synthesis (Czuwara-Ladykowska, Shirasaki et al. 
2001). MBG was seen to induce decreases in Fli-1 expression in cardiac and renal fibroblasts, 
which was dependent on the nuclear translocation of PKC delta from the cytoplasm. This 
translocation seems to be necessary for the phosphorylation and degradation of the Fli-1 
(Elkareh, Periyasamy et al. 2009). This is illustrated in figure 3. 
 
 
Fig. 3. Schematic showing how the signal cascade caused by cardiotonic steroids (CTS) 
causes the activation of phospholipase C (PLC) which then causes the translocation of 
protein kinase C (PKC, delta isoform) to the nucleus where it phosphorylates Fli-1. The 
phosphorylated Fli-1 is then rapidly degraded allowing for the disinhibition of procollagen 
synthesis and tissue fibrosis. 
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Since mineralocorticoid antagonists have been shown to ameliorate cardiac fibrosis, studies 
using spironolactone and canrenone have shown that both cause significant attenuation of 
fibrosis in-vivo as caused by experimental renal failure. Both these compounds also seemed 
to act as competitive inhibitors of CTS binding to Na/K ATPase and hence prevent MBG 
signaling (Tian, Shidyak et al. 2009). The role of CTS is thus clear in the pathogenesis of 
cardiac dysfunction with respect to calcium handling and the genesis of fibrosis. 
The presence of oxidative stress in the ESRD patients has been well documented (Fiorillo, 
Oliviero et al. 1998; Tetta, Biasioli et al. 1999). Most of the reactive oxygen species are 
produced by the mitochondria and a dysfunction in the mitochondria has been discussed 
above. Oxidative stress has been well known to affect cardiovascular function, cause 
endothelial dysfunction and hence promote atherosclerosis as well as cause increases in 
sympathetic activity (Miyazaki, Matsuoka et al. 2000; Wolf 2000; Zanzinger and Czachurski 
2000; Himmelfarb, Stenvinkel et al. 2002). Reactive aldehydes measured as carbonyl 
compounds can be formed as the end product of various oxidative reactions and have been 
shown to be elevated in uremia. These result in the formation of advanced glycation end 
products (AGE). These reactive aldehydes and AGE have been demonstrated in the 
pathogenesis of vascular dysfunction as well as fibrosis (Uchida 2000; Amann, Tornig et al. 
2002). The interaction of the AGE with specific receptors have also shown to increase the 
production of IL-6 and thus increasing the production of CRP in the liver and thereby 
propagating inflammation (Himmelfarb, Stenvinkel et al. 2002). Increases in CRP have a 
strong negative correlation with the levels of plasma tocopherol as shown by Thevenin et al. 
(Nguyen-Khoa, Massy et al. 2001) further showing that antioxidants are decreased in 
inflammation. Importantly it has been shown that tocopherol decreased fibrosis in the hearts 
of nephrectomized rats (Amann, Tornig et al. 2002). Hence chronic oxidative stress and 
damage seems to be an important mechanism in the pathogenesis of chronic inflammation 
and uremic cardiomyopathy. 
5. Conclusion 
Chronic renal failure is complicated by a cardiomyopathy that is characterized by LVH and 
diastolic dysfunction. CTS such as MBG are found in higher concentrations in the plasma of 
such patients. It is clear form several studies that these CTS are involved via signaling 
through Na/K ATPase in causing cardiomyocyte hypertrophy, impairing relaxation and 
inducing fibrosis by increased collagen synthesis, which seems to be dependent on 
increased oxidant stress. Other major factors possibly involved in the pathogenesis of this 
cardiomyopathy include hyperparathyroidism, chronic oxidant stress and the activation of 
the RAS aldosterone system. 
However mechanisms involving CTS and PTH and the interaction of the two systems seem 
to be emerging as the foremost candidate involved in the pathogenesis of uremic 
cardiomyopathy and may present prime targets for therapeutic interventions in the future. 
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Cardiomyopathy means "heart (cardio) muscle (myo) disease (pathy)". Currently, cardiomyopathies are
defined as myocardial disorders in which the heart muscle is structurally and/or functionally abnormal in the
absence of a coronary artery disease, hypertension, valvular heart disease or congenital heart disease
sufficient to cause the observed myocardial abnormalities. This book provides a comprehensive, state-of-the-
art review of the current knowledge of cardiomyopathies. Instead of following the classic interdisciplinary
division, the entire cardiovascular system is presented as a functional unity, and the contributors explore
pathophysiological mechanisms from different perspectives, including genetics, molecular biology,
electrophysiology, invasive and non-invasive cardiology, imaging methods and surgery. In order to provide a
balanced medical view, this book was edited by a clinical cardiologist.
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